NORSK-TITANIUM-AS
28.10.2021 18:56:12 CEST | Business Wire | Press release
Norsk Titanium AS (Norsk Titanium; Euronext: NTI), a global leader in Directed Energy Deposition (DED) additive manufacturing of aerospace-grade structural titanium components, announces today a significant advancement to their Rapid Plasma Deposition® (RPD® ) process. The company has successfully deployed and validated the internally developed RPD Builder™ computer-aided manufacturing tool for the first time, significantly shortening part development timelines.
“This is a tremendous accomplishment for Norsk Titanium,” said Nicholas Mayer, Norsk Titanium’s Vice President of Commercial. “RPD Builder™ is a significant enabler as we move into more industrial manufacturing and engineering services markets. It will give our customers added flexibility and allow them to explore part design options independent from our manufacturing engineering team.”
RPD Builder™ has been developed over the past three years and incorporates the full knowledge base of Norsk Titanium’s process metallurgy and machine controls into a single design toolkit. It enables users to rapidly translate customers’ final part geometries into optimized RPD® Form designs, and ultimately produces the code needed for any of Norsk Titanium’s Merke IV® RPD® machines to print the part preform regardless of location. Norsk Titanium’s manufacturing engineers have already employed the software on multiple part development efforts, reducing development time to as little as two days.
“Our Material Process & Product team has evaluated the microstructure of the deposited preforms and validated that the material produced with the RPD Builder™ is consistent with our proven process,” said Odd Terje Lium, Norsk Titanium’s Vice President of Engineering. “We were able to validate that the software is capable of producing complex geometries on multiple machines in both our development and production facilities.”
Initial application of RPD Builder™ comes as Norsk Titanium further expands into markets beyond commercial aerospace. The computer-aided manufacturing tool will be deployed under license with customers who desire more insight into part development than Norsk Titanium’s current built-to-print finished products.
About Norsk Titanium AS
Norsk Titanium AS was founded in 2007 in Norway and has pioneered the use of its patented additive manufacturing process, Rapid Plasma Deposition® (RPD® ). It has been supplying flight qualified structural components since 2017, and today the company operates manufacturing facilities in the State of New York and Norway. The company is distinguished in the aviation industry by its proprietary RPD® technology that transforms titanium wire into complex components suitable for structural and safety-critical applications. Norsk Titanium is a supplier to commercial aerospace Tier-1 manufacturers and is committed to cost-reducing aerostructures and jet engines for the world’s premier aerospace companies. RPD® is the world’s first FAA-approved process for manufacturing 3D-printed, structural titanium, delivering substantial lead-time and cost savings for aerospace, defense and commercial customers.
For the latest news, go to www.norsktitanium.com or follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005986/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain15.9.2026 13:30:00 CEST | Press release
- Vonn shares her experience using JOURNAVX to manage her acute pain after a career-altering injury at the 2026 Winter Games - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to over one million Americans. During the 2026 Winter Games in Milano Cortina, Lindsey suffered a serious crash during her downhill race. The fall resulted in multiple injuries that required immediate surgery and several additional procedures. Now, Lindsey is sharing her story and her personal experience treating her moderate-to-severe acute pain with JOURNAVX. “I have experienced countless injuries thro
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release
Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release
The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom